Please login to the form below

Not currently logged in
Email:
Password:

EASD: Novo’s degludec shows promise

Novo Nordisk's investigational basal insulin degludec is effective when used under stressed frequencies of injection in patients with type 2 diabetes, according to a study presented at the European Association for the Study of Diabetes meeting

Novo Nordisk's investigational basal insulin degludec is effective when used under stressed frequencies of injection in patients with type 2 diabetes.

Presenting study data at the European Association for the Study of Diabetes (EASD) meeting in Lisbon, Portugal, the Danish pharmaceutical company said degludec showed reductions in blood sugar levels of patients with type 2 diabetes, even when doses were given once-daily up to 40 hours apart.

The comparator insulin glargine was given to patients once-daily at a specific time of day according to its label instructions.

Professor David Matthews, Professor of Diabetic Medicine at the University of Oxford, UK, said the results were of potential benefit for patients as they would be able to sustain low blood sugar levels even if they missed an injection the previous day.

Young people with diabetes; patients in nursing homes; and carers who look after partners and family members with diabetes were cited by Matthews as groups who could often miss a daily insulin injection.

Overall rates of hypoglycaemia were 3.6 and 3.5 episodes per person per year for insulin degludec and insulin glargine respectively with rates of night-time hypoglycaemia being 0.6 and 0.7 episodes per person per year respectively.

The weight gain reported in patients taking degludec was more than in the glargine arm, but the difference was not significant according to Novo.

Novo's chief science officer Mads Krogsgaard Thomsen said that the company expects to file for regulatory approval of degludec in Europe and the US in the next few months.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics